Overview

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one of the dose levels to be tested will be more effective than placebo (inactive drug).
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Tofacitinib